Viracta Therapeutics, Inc. Stock Nasdaq
Equities
US92765F1084
Biotechnology & Medical Research
Financials (USD)
Sales 2024 * | - | Sales 2025 * | 2.33M | Capitalization | 31.69M |
---|---|---|---|---|---|
Net income 2024 * | -62M | Net income 2025 * | -83M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 13.6 x |
P/E ratio 2024 * |
-0.7
x | P/E ratio 2025 * |
-0.75
x | Employees | 40 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.2% |
Latest transcript on Viracta Therapeutics, Inc.
Managers | Title | Age | Since |
---|---|---|---|
Mark Rothera
CEO | Chief Executive Officer | 61 | 22-09-18 |
Chief Tech/Sci/R&D Officer | - | - | |
Darrel Cohen
CTO | Chief Tech/Sci/R&D Officer | 59 | 23-08-06 |
Members of the board | Title | Age | Since |
---|---|---|---|
Ivor Royston
BRD | Director/Board Member | 79 | 07-09-30 |
Thomas Darcy
BRD | Director/Board Member | 74 | 21-01-31 |
Barry Simon
BRD | Director/Board Member | 59 | 21-03-02 |
1st Jan change | Capi. | |
---|---|---|
+41.79% | 54.04B | |
+46.23% | 41.96B | |
-0.56% | 41.92B | |
-7.20% | 28.35B | |
+12.59% | 26.35B | |
-21.51% | 19B | |
+6.92% | 13B | |
+29.60% | 12.28B | |
+24.91% | 12.19B |